Rewiring KRAS-driven cancers through the ubiquitin–proteasome system: therapeutic opportunities with a focus on deubiquitinase
The development of KRAS inhibitors is explored, highlighting the challenges due to KRAS’s ‘undruggable’ nature and the success of covalent inhibitors such as sotorasib for KRASG12C mutant cancers, and the ubiquitin–proteasome system is highlighted as key regulators of KRAS stability and signaling networks, providing co...